Chemotherapy as a fine mist: could PIPAC reduce side effects for abdominal cancer patients?

NCT ID NCT04329494

First seen Jun 25, 2026 · Last updated Jul 23, 2026 · Updated 3 times

Summary

This early-phase trial tests a technique called PIPAC, which turns liquid chemotherapy into a fine mist sprayed directly into the abdomen during a minimally invasive surgery. It aims to see if this approach is safe and causes fewer side effects than standard chemotherapy. The study includes 49 adults with ovarian, uterine, appendiceal, colorectal, or gastric cancer that has spread to the lining of the abdomen.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Pressurized intraperitoneal aerosolized chemotherapy (PIPAC) with cisplatin, doxorubicin, oxaliplatin, leucovorin, fluorouracil, mitomycin, or irinotecan
What this could lead to
If successful, this could provide a less toxic way to deliver chemotherapy directly to abdominal tumors, potentially reducing side effects while controlling cancer spread.
What could go wrong
This is an early phase 1 trial with only 49 participants, so safety and effectiveness are not yet proven. The procedure is invasive and may cause complications or not improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLINICAL STAGE IV GASTRIC CANCER AJCC V8 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • City of Hope Medical Center

    RECRUITING

    Duarte, California, 91010, United States

  • Mayo Clinic in Florida

    ACTIVE_NOT_RECRUITING

    Jacksonville, Florida, 32224-9980, United States

  • Northwell Health Cancer Institute at Huntington

    RECRUITING

    Greenlawn, New York, 11740, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.